Abiomed (NSDQ:ABMD) today released data from a study which utilized its Impella 2.5 heart pump for hemodynamic support during high-risk percutaneous coronary interventions, touting reduced risk of acute kidney injury in patients with preexisting kidney disease and low ejection fraction.
Data from the study were recently published in the journal Circulation Research, the Danvers, Mass.-based company said.
“Above and beyond the well-known value of cardiac protection, these data show Protected PCI with Impella may also help prevent renal damage which may require dialysis or other costly treatments. This is an important finding, because it may allow interventionalists treating high-risk patients to perform more complete revascularization in those with multi-vessel coronary disease. We can potentially reduce the risks and costs associated with multiple PCI procedures performed in stages, which is how many high-risk patients are still treated today,” chief medical officer Dr. Seth Bilazarian said in a prepared statement.
Researchers examined procedure and clinical outcomes of 230 patients with ejection fractions of 35% or less before undergoing HRPCI, with half of the patients supported with Abiomed’s Impella 2.5 during the procedure.
Results from the study indicated that only 5.2% of Impella-supported patients developed AKI post-procedure, much lower than the 27.8% in the control cohort. Less than 1% of Impella-supported patients required post-operative hemodialysis, while 6.1% of patients in the control group required hemodialysis.
“A substantial number of high-risk PCI patients have both severely reduced left ventricular function and underlying kidney disease2, and during their procedure, these patients are exposed to high levels of contrast dye, which further compromises kidney function. We found that, despite severely reduced ejection fractions and baseline chronic kidney disease Impella-supported patients were six times less likely to develop acute kidney injury, underscoring the importance of Impella as part of a renal protective strategy during high-risk PCI,” study senior author & primary investigator Dr. Michael Flaherty of the University of Louisville School of Medicine said in a press release.